149
IRUS Total
Downloads
  Altmetric

Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease

File Description SizeFormat 
ExacRecoveryRevisionGD.docxAccepted version161.29 kBMicrosoft WordView/Open
Title: Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease
Authors: Donaldson, GC
Law, M
Kowlessar, B
Singh, R
Brill, SE
Allinson, JP
Wedzicha, JA
Item Type: Journal Article
Abstract: INTRODUCTION: COPD exacerbations are important and heterogeneous events, but the consequences of prolonged exacerbation recovery are unknown. METHODS: A cohort of 384 COPD patients (FEV1 % predicted 45.8 (SD 16.6) and a median exacerbation rate of 2.13 per year (IQR 1.0-3.2)) were followed for 1039 days (IQR 660-1814) between October 1995 and January 2013. Patients recorded daily worsening of respiratory symptoms and peak expiratory flow (PEF), and when stable underwent 3-monthly spirometry, and completed the St. George's Respiratory Questionnaire (SGRQ) annually. Exacerbations were diagnosed as two consecutive days with one major symptom plus another respiratory symptom. Exacerbation duration was defined as the time from onset to the day preceding two consecutive symptom-free and recovery in PEF as return to pre-exacerbation levels. RESULTS: 351 patients had 1 or more exacerbations. Patients with a longer symptom duration (mean 14.5 days) had a worse SGRQ total score (0.2 units per 1 day; p=0.040). A longer symptomatic duration was associated with a shorter interval between exacerbation recovery and onset of the next exacerbation (Hazard Ratio=1.004; p=0.013). For 257 (7.3%) exacerbations, PEF did not recover within 99 days. These exacerbations were associated with symptoms of a viral infection (cold and sore throat). Patients with these non-recovered exacerbations showed a 10.8 ml/year (p<0.001) faster decline in FEV1. CONCLUSION: Prolonged exacerbation symptomatic duration is associated with poorer health status and a greater risk of a new event. Exacerbations where lung function does not recover are associated with symptoms of viral infections and accelerated decline in FEV1.
Issue Date: 7-Jul-2015
Date of Acceptance: 6-Jul-2015
URI: http://hdl.handle.net/10044/1/25385
DOI: 10.1164/rccm.201412-2269OC
ISSN: 1535-4970
Publisher: American Thoracic Society
Start Page: 943
End Page: 950
Journal / Book Title: American Journal of Respiratory and Critical Care Medicine
Volume: 192
Issue: 8
Copyright Statement: © 2015 American Thoracic Society
Sponsor/Funder: Medical Research Council (MRC)
Guys & St Thomas NHS Foundation Trust
Funder's Grant Number: G0800570/2
RCF funding from LNW CRN
Keywords: COPD
Exacerbations
Non-recovery
Recovery
Risk interval
Science & Technology
Life Sciences & Biomedicine
Critical Care Medicine
Respiratory System
General & Internal Medicine
COPD
exacerbations
recovery
risk interval
nonrecovery
QUALITY-OF-LIFE
COPD EXACERBATIONS
RHINOVIRUS INFECTION
LUNG-FUNCTION
INFLAMMATORY MARKERS
DECLINE
HEALTH
AIRWAY
PHAGOCYTOSIS
MOXIFLOXACIN
COPD
exacerbations
nonrecovery
recovery
risk interval
Aged
Cohort Studies
Disease Progression
Female
Forced Expiratory Volume
Humans
Longitudinal Studies
Male
Middle Aged
Peak Expiratory Flow Rate
Pharyngitis
Proportional Hazards Models
Prospective Studies
Pulmonary Disease, Chronic Obstructive
Quality of Life
Recovery of Function
Respiratory Tract Infections
Risk Factors
Time Factors
Virus Diseases
Vital Capacity
Humans
Respiratory Tract Infections
Virus Diseases
Pharyngitis
Pulmonary Disease, Chronic Obstructive
Disease Progression
Vital Capacity
Peak Expiratory Flow Rate
Forced Expiratory Volume
Proportional Hazards Models
Risk Factors
Cohort Studies
Longitudinal Studies
Prospective Studies
Recovery of Function
Time Factors
Quality of Life
Aged
Middle Aged
Female
Male
Respiratory System
11 Medical and Health Sciences
Publication Status: Published
Online Publication Date: 2015-07-07
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine